Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular signatures and spatial distribution of disease-associated cellular populations in early-onset Alzheimer's disease mouse brain

ABSTRACT: Alzheimer's disease (AD) is a multifaceted neurodegenerative disorder. Grasping the pathological transformations in early-phase AD is important. Integrating single-cell and spatial transcriptomics with the pathophysiology of AD from the same origin permits to delineate molecular characteristics and spatial arrangement of cellular populations without individual differences, however, such experimental designs have been ignored in current studies. Here, we use a single-source experimental framework to create a multimodal dataset of disease-susceptible region in early-onset Alzheimer's Disease (EOAD) mouse. Predicated on amyloid-beta (Aβ) immunopathology, a profile of disease-associated alterations is discerned. Mature myelinating oligodendrocytes within fiber tracts exhibit compromised fatty acid synthesis and energy-related processes. Region-specific glutamatergic neurons demonstrate impaired synaptic formation, coupled with transcriptomic modifications that encompass energy homeostasis, lipid metabolism and cellular adhesion. Disease-associated astrocytes, aggregating around Aβ deposits, exhibit neuron-related changes in oxidative phosphorylation (OxPhos) and metal ion responses. This investigation serves as a resource for exploring disease signature across multimodal, which provides a basis for finding the progression mechanisms of AD.

ORGANISM(S): Mus musculus

PROVIDER: GSE253570 | GEO | 2025/06/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Pathway-based network medicine identifies novel natural products for Alzheimer's disease

Project description:Natural products exhibit potential as candidates for developing multi-target agents for Alzheimer's disease treatment. The aim of this study is to utilize network-based medicine to identify novel natural products for Alzheimer's disease, and investigate their efficacy and mechanisms of action. In this study, we identified (-)-Vestitol and Salviolone as new potential natural products for treating Alzheimer's disease via an Alzheimer's disease-related pathway-gene network. Both natural products improved the cognition of APP/PS1 transgenic mice, reduced Aβ deposition, and lowered soluble toxic Aβ levels in the brain. Notably, a synergistic effect was observed when the two natural products were combined. Transcriptomic analysis and qRT-PCR experiments revealed that the synergistic mechanism of (-)-Vestitol and Salviolone combination is associated with the regulation of a broader range of AD-related pathways and genes, particularly the neuroactive ligand-receptor interaction pathway and calcium signaling pathway.

2025-02-19 | GSE270100 | GEO

Transcriptome sequencing of hippocampal tissue of APP/PS1 mice treated with rotating magnetic field for 12 months

Project description:Amyloid beta (Aβ) monomers aggregate to form fibrils and amyloid plaques, which is one of the important mechanisms in the pathogenesis of Alzheimer's disease (AD). Since the Aβ1-42 aggregation has prominent role in plaque formation, which eventually lead to the patient's brain lesions and cognitive impairment, an increasing number of studies have been devoted to reduce Aβ aggregation process to slow down AD progression. Since the diphenylalanine (FF) sequence is critical for amyloid aggregation, and it has been shown that magnetic fields can affect the alignment of peptide assembly due to the diamagnetic anisotropy of aromatic rings, here we used a moderate-intensity rotating magnetic field (RMF) to explore its effect on Aβ aggregation and AD pathogenesis. Our data showed that RMF can directly inhibit Aβ amyloid fibril formation and reduce Aβ-induced cytotoxicity on neural cells in vitro. Using the AD mouse model APP/PS1, we found that the RMF can restore their motor ability to the healthy control level. Their cognitive impairments, including exploration ability, spatial and non-spatial memory abilities, were also significantly alleviated. Tissue examinations reveal that RMF has reduced amyloid plaque accumulation, attenuated microglial activation ,and reduced oxidative stress in the APP/PS1 mouse brain. Therefore, our data demonstrate the great potential of RMF to be developed as a non-invasive, high-penetration physical approach to be applied in the treatment of AD.

2024-06-06 | GSE269222 | GEO

Increased neutrophils in inflammatory bowel disease accelerate the accumulation of amyloid plaques in the mouse model of Alzheimer's disease

Project description:Alzheimer's disease (AD) is one of the neurodegenerative diseases and characterized by the appearance and accumulation of amyloid-β (Aβ) aggregates and phosphorylated tau with aging. We performed scRNAseq of immene cells in the brain from WT and AD mice.

2022-12-01 | GSE214747 | GEO

Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease

Project description:While amyloid-β (Aβ) plaques are considered a hallmark of Alzheimer's disease, clinical trials focused on targeting gamma secretase, an enzyme involved in aberrant Aβ peptide production, have not led to amelioration of AD symptoms or synaptic dysregulation. Screening strategies based on mechanistic, multi-omics approaches that go beyond pathological readouts can aid in the evaluation of therapeutics. Using early-onset Alzheimer's (EOFAD) disease patient lineage PSEN1A246E iPSC-derived neurons, we performed RNA-seq to characterize AD-associated endotypes, which are in turn used as a screening evaluation metric for two gamma secretase drugs, the inhibitor Semagacestat and the modulator BPN-15606.

2022-01-27 | GSE95673 | GEO

Temporal impact of sepsis on Alzheimer's disease pathology and neuroinflammation

Project description:Epidemiological evidence has reported an associative link between sepsis survivorship and increased risk of dementia, particularly Alzheimer's disease (AD). Paradoxically, population studies show females are less susceptible to sepsis but more vulnerable to post-sepsis dementia, including Alzheimer's disease (AD). Here, we examined the temporal impacts of sepsis on AD pathology using an AD-model (TgCRND8) and wild-type mice, assessing outcomes at 7 days and 3 months post-sepsis. Following 7-days recovery, all male and female post-septic mice showed robust systemic immune activation. At this time, the female AD-model mice accumulated higher hippocampal amyloid-beta (Aβ) and upregulated AD-type transcriptomic signature. On the other hand, male AD-model mice showed no Aβ changes. Notably, wild-type post-septic males, but not females, displayed robust astrocytosis, with little change in microglial proliferation. By 3 months post-sepsis, microgliosis was specifically elevated in wild-type females, indicating a prolonged central immune response. At this time, both male and female AD-model mice showed exacerbated Aβ and anxiety. Gene network analysis revealed a stronger female immune response, while the male response was linked to estrogen receptor (ESR) signaling, with increased ERα protein observed in the brains of post-septic AD males. Together, our data highlights a sex-dimorphic temporal response in post-sepsis neuroinflammation, with ESR signaling playing a key role in males, while Aβ burden is affected similarly in both males and females.

2025-05-31 | GSE292277 | GEO

GPR34 senses demyelination to promote neuroinflammation and cognition impairment in Alzheimer's disease

Project description:Sterile neuroinflammation initiated by damage-associated molecular patterns (DAMPs) has been regarded as an important driver in Alzheimer's disease (AD) and can occur prior or independently of the deposition of extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles (NFTs). Genetic ablation or pharmacological inhibition of GPR34 reduced microglia activation, Aβ deposition and cognition impairment. Moreover, GPR34 inhibition prevented aging associated neuroinflammation and cognition impairment without the presence of Aβ plaques.

2025-02-05 | GSE216209 | GEO

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease [dataset3]

Project description:Alzheimer’s disease (AD) therapies utilizing amyloid-β (Aβ) immunization have shown potential in clinical trials. Yet, the mechanisms driving Aβ clearance in the immunized AD brain remain unclear. Here, we use spatial transcriptomics to explore the effects of both active and passive Aβ immunization in the AD brain. We compare actively immunized AD patients with nonimmunized AD patients and neurologically healthy controls, identifying distinct microglial states associated with Aβ clearance. Using high-resolution spatial transcriptomics alongside single-cell RNA sequencing, we delve deeper into the transcriptional pathways involved in Aβ removal after lecanemab treatment. We uncover spatially distinct microglial responses that vary by brain region. Our analysis reveals upregulation of the triggering receptor expressed on myeloid cells 2 (TREM2) and apolipoprotein E (APOE) in microglia across immunization approaches, which correlate positively with antibody responses and Aβ removal. Furthermore, we show that complement signaling in brain myeloid cells contributes to Aβ clearance after immunization. These findings provide new insights into the transcriptional mechanisms orchestrating Aβ removal and shed light on the role of microglia in immune-mediated Aβ clearance. Importantly, our work uncovers potential molecular targets that could enhance Aβ-targeted immunotherapies, offering new avenues for developing more effective therapeutic strategies to combat AD.

2025-03-03 | GSE263079 | GEO

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease [dataset2]

2025-03-03 | GSE263038 | GEO

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease [dataset1]

2025-03-03 | GSE263034 | GEO

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease

2025-03-03 | GSE282928 | GEO